Antagonism between bacteriostatic and bactericidal antibiotics is prevalent

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 8, 2014, Pages 4573-4582

  Ocampo, Paolo S ^a,c   Lázár, Viktória ^b   Papp, Balázs ^b   Arnoldini, Markus ^a,c   Zur Wiesch, Pia Abel ^d   Busa Fekete, Róbert ^e   Fekete, Gergely ^b   Pál, Csaba ^b   Ackermann, Martin ^a,c   Bonhoeffer, Sebastian ^a  

^a ETH ZURICH   (Switzerland)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c Department of Environmental Microbiology ^*  (Switzerland)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC ANTIBIOTIC; CYTOSTATIC AGENT;

ANTAGONISTS AND INHIBITORS; DRUG ANTAGONISM; DRUG EFFECTS; ESCHERICHIA COLI; GROWTH, DEVELOPMENT AND AGING; HIGH THROUGHPUT SCREENING; MICROBIAL SENSITIVITY TEST; MICROFLUIDIC ANALYSIS; SINGLE CELL ANALYSIS; TIME LAPSE IMAGING;

ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; CYTOSTATIC AGENTS; DRUG ANTAGONISM; ESCHERICHIA COLI; HIGH-THROUGHPUT SCREENING ASSAYS; MICROBIAL SENSITIVITY TESTS; MICROFLUIDIC ANALYTICAL TECHNIQUES; SINGLE-CELL ANALYSIS; TIME-LAPSE IMAGING;

EID: 84905403724     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02463-14     Document Type: Article

References (39)

1. Bonhoeffer S, Lipsitch M, Levin BR. 1997. Evaluating treatment protocols to prevent antibiotic resistance. Proc. Natl. Acad. Sci. U. S. A. 94:12106-12111. http://dx.doi.org/10.1073/pnas.94.22.12106.
2. Hand K. 2006. Tuberculosis: pharmacological management. Hosp. Pharm. 13:81-85.
3. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, D'Arminio Monforte A, Yust I, Bruun JN, Phillips AN, Lundgren JD, EuroSIDA Study Group. 1998. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 352:1725-1730. http://dx.doi.org/10.1016/S0140-6736 (98) 03201-2.
4. WHO. 2010. WHO guidelines for the treatment ofmalaria, 2nd ed. WHO, Geneva, Switzerland.
5. Gilbert DN, Moellering RC, Eliopoulos GM, Chambers HF, Saag MS (ed). 2010. The Sanford guide to antimicrobial therapy, 40th ed. Antimicrobial Therapy, Inc., Sperryville, VA.
6. Cottarel G, Wierzbowski J. 2007. Combination drugs, an emerging option for antibacterial therapy. Trends Biotechnol. 25:547-555. http://dx.doi.org/10. 1016/j.tibtech.2007.09.004.
7. Forrest GN, Tamura K. 2010. Rifampin combination therapy for nonmycobacterial infections. Clin. Microbiol. Rev. 23:14-34. http://dx.doi.org/10.1128/CMR.00034-09.
8. Cunha BA. 2004. Therapeutic implications of antibacterial resistance in community-acquired respiratory tract infections in children. Infection 32:98-108. http://dx.doi.org/10.1007/s15010-004-3065-5.
9. Ankomah P, Johnson P J T, Levin BR. 2013. The pharmaco-, population and evolutionary dynamics of multi-drug therapy: experiments with S. aureus and E. coli and computer simulations. PLoS Pathog. 9:e1003300. http://dx.doi.org/10. 1371/journal.ppat.1003300.
10. Johansen HK, Jensen TG, Dessau RB, Lundgren B, Frimodt-Moller N. 2000. Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vivo. J. Antimicrob. Chemother. 46:973-980. http://dx.doi.org/ 10.1093/jac/46.6.973.
11. Cates JE, Christie RV, Garrod LP. 1951. Penicillin-resistant subacute bacterial endocarditis treated by a combination of penicillin and streptomycin. Br. Med. J. 1:653-656.
12. Garrod L. 1972. Causes of failure in antibiotic treatment. Br. Med. J. 4:473-476. http://dx.doi.org/10.1136/bmj.4.5838.473.
13. Yeh PJ, Hegreness MJ, Aiden AP, Kishony R. 2009. Drug interactions and the evolutionofantibiotic resistance. Nat. Rev. Microbiol. 7:460-466. http://dx.doi.org/10.1038/nrmicro2133.
14. Chait R, Craney A, Kishony R. 2007. Antibiotic interactions that select against resistance. Nature 446:668-671. http://dx.doi.org/10.1038/nature05685.
15. Hegreness M, Shoresh N, Damian D, Hartl D, Kishony R. 2008. Accelerated evolution of resistance in multidrug environments. Proc. Natl. Acad. Sci. U. S. A. 105:13977-13981. http://dx.doi.org/10.1073/pnas.0805965105.
16. Nitzan O, Supornitzky U, Kennes Y, Chazan B, Raz R, Colodner R. 2010. Is chloramphenicol making a comeback? Isr. Med. Assoc. J. 12:371-374.
17. Falagas ME, Grammatikos AP, Michalopoulos A. 2008. Potential of old-generation antibiotics to address current need for new antibiotics. Expert Rev. Anti Infect. Ther. 6:593-600. http://dx.doi.org/10.1586/14787210.6.5.593.
18. Wilson G, Miles A. 1964. Topley and Wilson's principles of bacteriology and immunity, 5th ed. Edward Arnold, London, United Kingdom.
19. Jawetz E, Gunnison J. 1953. Antibiotic synergism and antagonism: an assessment of the problem. Pharmacol. Rev. 5:175-192.
20. Jawetz E, Gunnison J, Coleman VR. 1954. Observations on the mode of action of antibiotic synergism and antagonism. J. Gen. Microbiol. 10:191-198. http://dx.doi.org/10.1099/00221287-10-2-191.
21. Lázár V, Pal Singh G, Spohn R, Nagy I, Horváth B, Hrtyan M, Busa-Fekete R, Bogos B, Méhi O, Csörgo B, Pósfai G, Fekete G, Szappanos B, Kégl B, Papp B, Pál C. 2013. Bacterial evolution of antibiotic hypersensitivity. Mol. Syst. Biol. 9:700. http://dx.doi.org/10.1038/msb.2013.57.
22. Yeh P, Tschumi AI, Kishony R. 2006. Functional classification of drugs by properties of their pairwise interactions. Nat. Genet. 38:489-494. http://dx.doi.org/10.1038/ng1755.
23. Warringer J, Blomberg A. 2003. Automated screening in environmental arrays allows analysis of quantitative phenotypic profiles in Saccharomyces cerevisiae. Yeast 20:53-67. http://dx.doi.org/10.1002/yea.931.
24. Rasmussen CE, Williams C K I. 2006. Gaussian processes for machine learning. MIT Press, Cambridge, MA.
25. Drusano GL, D'Argenio DZ, Preston SL, Barone C, Symonds W, La Fon S, Rogers M, Prince W, Bye A, Bilello JA. 2000. Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir. Antimicrob. Agents Chemother. 44:1655-1659. http://dx.doi.org/10.1128/AAC.44.6. 1655-1659.2000.
26. Drusano GL, D'Argenio DZ, Symonds W, Bilello PA, McDowell J, Sadler B, Bye A, Bilello JA. 1998. Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro. Antimicrob. Agents Chemother. 42:2153-2159.
27. Greco WR, Bravo G, Parsons JC. 1995. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47:331-385.
28. Loewe S. 1953. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3:285-290.
29. Cokol M, Chua HN, Tasan M, Mutlu B, Weinstein ZB, Suzuki Y, Nergiz ME, Costanzo M, Baryshnikova A, Giaever G, Nislow C, Myers CL, Andrews BJ, Boone C, Roth FP. 2011. Systematic exploration of synergistic drug pairs. Mol. Syst. Biol. 7:544. http://dx.doi.org/10.1038/msb.2011.71.
30. Lehar J, Zimmerman GR, Krueger AS, Molnar RA, Ledell JT, Heilbut AM, Short GF, III, Giusti LC, Nolan GP, Magid OA, Lee MS, Borisy AA, Stockwell BR, Keith CT. 2007. Chemical combination effects predict connectivity in biological systems. Mol. Syst. Biol. 3:80. http://dx.doi.org/10.1038/msb4100116.
31. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-7th ed. Clinical and Laboratory Standards Institute, Wayne, PA
32. Wang P, Robert L, Pelletier J, Dang WL, Taddei F, Wright A, Jun. S. 2010. Robust growth of Escherichia coli. Curr. Biol. 20:1099-1103. http://dx.doi.org/10.1016/j.cub.2010.04.045.
33. Loewe S. 1928. Die quantitiven Probleme der Pharmakologie. Ergeb. Physiol. 27:47-187. http://dx.doi.org/10.1007/BF02322290.
34. Bollenbach T, Quan S, Chait R, Kishony R. 2009. Nonoptimal microbial response to antibiotics underlies suppressive drug interactions. Cell 139:707-718. http://dx.doi.org/10.1016/j.cell.2009.10.025.
35. Cozens RM, Tuomanen E, Tosch W, Zak O, Suter J, Tomasz A. 1986. Evaluation of the bactericidal activity of β-lactam antibiotics on slowly growing bacteria cultured in the chemostat. Antimicrob. Agents Chemother. 29:797-802. http://dx.doi.org/10.1128/AAC.29.5.797.
36. Eng R H K, Padberg FT, Smith SM, Tan EN, Cherubin CE. 1991. Bactericidal effects of antibiotics on slowly growing and nongrowing bacteria. Antimicrob. Agents Chemother. 35:1824-1828. http://dx.doi.org/10.1128/AAC.35.9.1824.
37. Pankey G, Sabath L. 2004. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin. Infect. Dis. 38:864-870. http://dx.doi.org/10.1086/381972.
38. Yao Z, Kahne D, Kishony R. 2012. Distinct single-cell morphological dynamics under [3-lactam antibiotics. Mol. Cell 48:705-712. http://dx.doi.org/ 10.1016/j.molcel.2012.09.016.
39. Allison K, Brynildsen M, Collins J. 2011. Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature 473:216-220. http://dx.doi.org/10.1038/nature10069.